Evaluation of a modified interferon-gamma release assay for the diagnosis of latent tuberculosis infection in adult and paediatric populations that enables delayed processing

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 11-12, 2010, Pages 845-850

  Wang, Shu Hua ^a,b   Powell, Dwight A ^a,c   Nagaraja, Haikady N ^b   Morris, Jessica D ^b   Schlesinger, Larry S ^a,b   Turner, Joanne ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; REAGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CHILD; CLINICAL LABORATORY; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PHYSICIAN; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TUBERCULIN TEST;

ADOLESCENT; ADULT; AGED; BACTERIOLOGICAL TECHNIQUES; BLOOD; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOASSAY; INFANT; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TIME FACTORS; YOUNG ADULT;

EID: 78549282158     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.498021     Document Type: Article

References (11)

1. World Health Organization. Tuberculosis facts. Geneva, Switzerland: WHO; 2008.
2. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999 - 2000. Am J Respir Crit Care Med 2008;177:348-55.
3. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060-7.
4. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49(RR-6):1-51.
5. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15): 49-55.
6. Pai M, Zwerling A, Menzies D. Systematic review: T -cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
7. QuantiFERON-TB Gold. Carnegie, Australia: Cellestis Ltd; 2009. Available at: http://www.cellestis.com/ (accessed December 2009).
8. T.SPOT .TB Test. Abingdon, UK: Oxford Immunotec Ltd; 2009. Available at: http://www.oxfordimmunotec.com/ (accessed December 2009).
9. Smith SG, Joosten SA, Verscheure V, Pathan A, McShane H, Ottenhoff T, et al. Identifi cation of major factors infl uencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One 2009;4:e7972.
10. Lenders L, Meldau R, van Zyl-Smit R, Woodburne V, Maredza A, Cashmore T, et al. Comparison of same day versus delayed enumeration of TB-specifi c T cell responses. J Infect 2010;60:344-50.
11. Lobue P. Provisional CDC recommendations for the use of interferon-gamma release assays to detect Mycobacterium tuberculosis infection in the United States. Program 50. Infectious Diseases Society of America, 47 th Annual Meeting;October 28 - November 1, 2009. Philadelphia, PA, USA; 2009.